Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-25T16:41:20.735Z Has data issue: false hasContentIssue false
  • English
  • Français

COST-EFFECTIVENESS OF ALEMTUZUMAB FOR T-CELL PROLYMPHOCYTIC LEUKEMIA

Published online by Cambridge University Press:  14 September 2012

Lanting Lu ,
Jaime Peters ,
Chris Roome  and
Ken Stein
Lanting Lu
Affiliation:
Unviersity of Exeter email: lulanting@gmail.com
Jaime Peters
Affiliation:
University of Exeter
Chris Roome
Affiliation:
NHS Devon
Ken Stein
Affiliation:
University of Exeter
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aim of this study was to evaluate the cost-effectiveness of alemtuzumab (CAMPATH-1H) compared with conventional chemotherapy in people with T-cell prolymphocytic leukemia (T-PLL).

Methods: We developed a decision-analytic model to assess the costs and benefits of alemtuzumab or conventional therapy based on their effects on quality of life of patients. The main outcome was the incremental cost-effectiveness ratio incorporating costs per additional quality-adjusted life-year (QALY) gained over lifetime. Due to the limited data available, a large number of assumptions had to be made to construct the cost-utility model. One-way, multi-way, and probabilistic sensitivity analyses (PSA) were conducted to explore the impact of these uncertainties. Expected values of perfect information were also calculated for four specific scenarios.

Results: Depending on different key assumptions made, the PSA suggested distinct conclusions using a willingness-to-pay threshold of 30,000 GBP per QALY gained. Using this threshold, the probability that alemtuzumab would be cost-effective varies from 0 percent to 53 percent for the four modeled scenarios. Population expected value of perfect information analysis suggests that resolving the parameter uncertainty in the analysis for people with T-PLL in the United Kingdom would have considerable value—up to 5.3 million euro.

Conclusions: Alemtuzumab appears more likely to be cost-effective if used earlier in the course of T-PLL and where it replaces the use of multiple alternative therapies. However, cost-effectiveness is highly uncertain and future research is clearly justified. Nevertheless, our analysis demonstrates the feasibility of considering the cost-effectiveness of an agent despite the presence of significant uncertainty to provide appropriate assessment information to policy makers.

Keywords

Cost-utility analysisAlemtuzumabT-cell prolymphocytic leukemiaValue of information analysisProbabilistic sensitivity analysis
Type
ASSESSMENTS
Information
International Journal of Technology Assessment in Health Care , Volume 28 , Issue 3 , July 2012 , pp. 241 - 248
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Dearden, C.Clinical case review: Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched Unrelated Donor Allogeneic Stem Cell Transplantation. Clin Adv Haematol Oncol. 2007;5:882–884.Google Scholar
2.Dearden, CE, Matutes, E, Cazin, B, et al.High remission rate in T-cell prolymphocytic leukaemia with CAMPATH-1H. Blood. 2001;98:1721–1726.CrossRefGoogle ScholarPubMed
3.Department of Health (UK). NHS reference costs. London: Department of Health; 2009.Google Scholar
4.General Medical Council. GMC guidance: Good practice in prescribing medicines. London: General Medical Council; 2008.Google Scholar
5.Genzyme Therapeutics. Summary of product characteristics - MabCampath 30mg/ml concentrate for solution for infusion. Cambridge, MA: Electronic Medicines Compendium; 2010.Google Scholar
6.Joint Formulary Committee. British National Formulary No. 58. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009.Google Scholar
7.Keating, MJ, Cazin, B, Coutré, S, et al.Campath-1H treatment of T-cell prolymphocytic leukaemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20:205–213.CrossRefGoogle ScholarPubMed
8.Kruspe, RC, Ashraf, KK, Foran, JM, Salzman, DE, Reddy, VV, Vaughan, WP. Successful treatment of T-cell prolymphocytic leukaemia with full-intensity conditioning followed by matched unrelated donor allogenic stem cell transplantation. Clin Adv Haematol Oncol. 2007;5:882–884.Google Scholar
9.Main, C, Pitt, M, Moxham, T, Stein, K, Peninsula Technology Assessment Group (PenTAG). The clinical and cost-effectiveness of Rituximab for the 1st line treatment of Chronic Lymphocytic Leukaemia: An evidence review of the submission from Roche: NICE; 2009.Google Scholar
10.Matutes, E, Brito-Babapulle, V, Swansbury, J, et al.Clinical and Laboratory features of 78 cases of T-prolymphocytic leukaemia. Blood. 1991;78:3269–3274.CrossRefGoogle Scholar
11.National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008.Google Scholar
12.National Institute for Health and Clinical Excellence. Technology appraisal guidance: Rituximab for the first-line treatment of chronic lymphocytic leukemia. London: NICE; 2009.Google Scholar
13.Peninsula Health Technology Commissioning Group. Alemtuzumab in chronic lymphocytic leukaemia. Appendix 9. 2009. London: Peninsula Health Technology Commissioning Group.Google Scholar
14.Schnitzler, M, Hasskarl, J, Egger, M, Bertz, H, Finke, J. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant. 2009;15:910–918.CrossRefGoogle ScholarPubMed
Supplementary material: File

Lu supplementary figure 1

Lu supplementary figure 1

Download Lu supplementary figure 1(File)
File 36.4 KB
Supplementary material: File

Lu supplementary figure 2

Lu supplementary figure 2

Download Lu supplementary figure 2(File)
File 32.3 KB
Supplementary material: File

Lu supplementary figure 3

Lu supplementary figure 3

Download Lu supplementary figure 3(File)
File 27.6 KB
Supplementary material: File

Lu supplementary figure 4

Lu supplementary figure 4

Download Lu supplementary figure 4(File)
File 28.7 KB
Supplementary material: File

Lu supplementary figure 5

Lu supplementary figure 5

Download Lu supplementary figure 5(File)
File 68.1 KB
Supplementary material: File

Lu supplementary figure 6

Lu supplementary figure 6

Download Lu supplementary figure 6(File)
File 107.5 KB